{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"cAMeLot-1","nct_id":"NCT04811560","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=camelot-1-nct04811560. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"cAMeLot-1","arms":[{"description":"Participants in Phase 1 Part 1 (dose escalation) will receive bleximenib orally. The dose levels will be escalated based on the dose limiting toxicities (DLT) evaluation by Study Evaluation Team (SET) until the recommended Phase 2 Doses (RP2Ds) have been identified. Participants in Phase 1 Part 2 (dose expansion) will receive bleximenib orally at the RP2D(s) determined in Part 1. In Phase 2 participants will receive bleximenib at the RP2D to evaluate anti-leukemia activity and demonstrate acceptable safety at the RP2D(s).","label":"Bleximenib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-09-22","type":"ESTIMATED"},"conditions":["Acute Leukemia"],"enrollment":{"count":420,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Bleximenib","otherNames":["JNJ-75276617"],"type":"DRUG"}],"last_update":"2026-11-04","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (cAMeLot-1)","overall_status":"RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2028-12-29","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability","timeFrame":"Up to 4 years and 9 months"},{"measure":"Phase 1: Number of Participants with AEs by Severity","timeFrame":"Up to 4 years and 9 months"},{"measure":"Phase 1: Part 1: Percentage of Participants with Dose-Limiting Toxicity (DLT)","timeFrame":"Up to 28 days Cycle 1"},{"measure":"Phase 2: Rate of Complete Remission or Complete Remission with Partial Hematologic Recovery (CR/CRh)","timeFrame":"Up to 4 years and 9 months"}],"references":[{"citation":"Kwon MC, Thuring JW, Querolle O, Dai X, Verhulst T, Pande V, Marien A, Goffin D, Wenge DV, Yue H, Cutler JA, Jin C, Perner F, Hogeling SM, Shaffer PL, Jacobs F, Vinken P, Cai W, Keersmaekers V, Eyassu F, Bhogal B, Verstraeten K, El Ashkar S, Perry JA, Jayaguru P, Barreyro L, Kuchnio A, Darville N, Krosky D, Urbanietz G, Verbist B, Edwards JP, Cowley GS, Kirkpatrick R, Steele R, Ferrante L, Guttke C, Daskalakis N, Pietsch EC, Wilson DM, Attar R, Elsayed Y, Fischer ES, Schuringa JJ, Armstrong SA, Packman K, Philippar U. Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias. Blood. 2024 Sep 12;144(11):1206-1220. doi: 10.1182/blood.2023022480.","pmid":"38905635","type":"DERIVED"}],"start_date":{"date":"2021-05-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)","url":"https://clinicaltrials.gov/study/NCT04811560"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/camelot-1-nct04811560"}